A new bead-based human platelet antigen antibodies detection assay versus the monoclonal antibody immobilization of platelet antigens assay

• Published in: Transfusion (Philadelphia, Pa.) Pa.), 2014-06, Vol.54 (6), p.1486-1492
• Main Authors: Porcelijn, Leendert, Huiskes, Elly, Comijs-van Osselen, Ilona, Chhatta, Aniska, Rathore, Vipul, Meyers, Matthew, de Haas, Masja
• Format: Article
• Language: English
• Subjects: Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Antibodies - analysis; Antibodies - immunology; Antibodies, Monoclonal - analysis; Antibodies, Monoclonal - immunology; Antigens; Antigens, Human Platelet - immunology; Biological and medical sciences; Biological Assay - methods; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis; Humans; Medical sciences; Transfusions. Complications. Transfusion reactions. Cell and gene therapy
• ISSN: 0041-1132; 1537-2995
• DOI: 10.1111/trf.12509

Background The performance of a newly developed Luminex bead‐based platelet (PLT) antibody detection method (PAKLx) was compared with the monoclonal antibody immobilization of PLT antigens (MAIPA) assay and the LifeScreen Deluxe Luminex bead‐based HLA Class I antibody detection method (LMX). Study Design and Methods Six sera containing anti‐human PLT antigen (HPA)‐1a (n = 2), HPA‐1b, HPA‐2b, HPA‐3a, or HPA‐5b were tested in titration. A total of 194 sera, including HPA‐1a, ‐1b, ‐2a, ‐2b, ‐3a, ‐5a, and ‐5b antibodies with or without HLA antibodies (n = 63); glycoprotein (GP) IV antibodies (n = 1); PLT autoantibodies (n = 3); HLA antibodies (n = 45); and samples with no PLT‐reactive antibodies (n = 82), were tested in both assays. Results Comparable levels of sensitivity were obtained for the MAIPA and PAKLx. The PAKLx showed four (6%) false‐negative results in 67 sera with HPA or GP‐reactive antibodies: anti‐HPA‐3a (n = 1) or anti‐HPA‐5b (n = 3). The PAKLx showed in 10 of the total 194 samples (5%) the presence of antibodies not detected by the MAIPA. This concerned broadly GP‐reactive antibodies (n = 7), anti‐GPIIb/IIIa combined with anti‐HPA‐3a (n = 1), anti‐HPA‐1a (borderline, n = 1), and anti‐GPIV (n = 1). Testing 175 sera for anti‐HLA Class I antibodies in the PAKLx and LMX showed four discrepant results: PAKLx negative and LMX positive, n = 3 and n = 1, respectively. Conclusion For the vast majority of the specimens tested (93%) the results of the PAKLx were in concordance with the MAIPA. The PAKLx is a fast, easy to perform, and sensitive PLT antibody screening method.